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E-mail address: jekim@khu.ac.kr (J.-E. Kim).One of the functions mediated by sirtuin 1 (SIRT1), the NAD+-dependent protein deacetylase, has
been suggested to be neuroprotective since resveratrol, a SIRT1 activator, inhibits 1-methyl-4-phen-
ylpyridinium ion (MPP+)-induced cytotoxicity. In this study, we show that SIRT1 siRNA transfection
blocks MPP+-induced apoptosis in SH-SY5Y cells. The ratio of potential pro-apoptotic BNIP2 to anti-
apoptotic BCL-xL was attenuated in SIRT1-deﬁcient cells following MPP+ treatment. In addition,
BNIP2 shRNA-transfected cells showed reduced cleavage of PARP-1, while BNIP2 overexpression
intensiﬁed the cleavage in MPP+-treated SH-SY5Y cells, suggesting that BNIP2 participates in the
MPP+-induced apoptosis. Overall, these data imply that SIRT1 may mediate MPP+-induced cytotox-
icity, possibly through the regulation of BNIP2.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The NAD+-dependent protein deacetylase sirtuin 1 (SIRT1), a
member of the sirtuin family, is an enzyme that acts on a variety
of substrates. SIRT1 substrates are mostly transcriptional regula-
tors such as p53, NF-jB, MyoD, PGC-1a, FOXO, AR, ERa and LXR,
thereby mediating a transcriptional activation or transcriptional
repression [1]. Due to its diverse substrates, SIRT1 regulates vari-
ous biological functions including cell proliferation, differentiation,
DNA repair, glucose metabolism, lipid metabolism, mitochondrial
biogenesis, apoptosis, autophagy and inﬂammation [2]. Further-
more, it has been suggested that SIRT1 controls pathogenesis of
certain diseases, which are cancer, metabolic syndromes, cardio-
vascular diseases and neurodegenerative diseases [3].
Extensive studies investigating the role of SIRT1 in neurodegen-
eration are currently under investigation. SIRT1 and its activator,
resveratrol, have been shown to play a protective role in the model
of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD)
[4–8]. Treatment with SIRT1 small interfering RNA (siRNA), or sirt-
inol, an SIRT1 inhibitor, blocks axonal protection in response to ax-
onal injury [9]. Resveratrol inhibits neuronal cell death in the
mouse model of Huntington’s disease (HD), which is induced bychemical Societies. Published by E
; SIRT1, sirtuin 1
gdaemun-gu, Seoul 130-701,the mutant polyglutamine protein, huntingtin [10]. In addition,
the protective role of resveratrol has been studied in a model of
Parkinson’s disease (PD). Resveratrol decreases the death of dopa-
minergic cells treated with 6-hydroxydopamine (6-OHDA), or with
the dopaminergic neurotoxins, 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) and its active metabolite, 1-methyl-4-phen-
ylpyridinium (MPP+) [11–18]. Overall, it has been suggested that
the activation of SIRT1 confers protection against neurodegenera-
tion in the disease, ALS, AD, HD and PD.
However, several recent ﬁnding have challenged the protective
effect of SIRT1 in PD. Previously, it was widely believed that resve-
ratrol protects cells from dopaminergic insults through SIRT1 acti-
vation. However, several groups have reported that resveratrol
does not directly activate the catalytic activity of the SIRT1 enzyme
in vitro [19,20]. Given that a SIRT1 inhibitor does not reverse res-
veratrol-mediated neuroprotection following MPP+ treatment, it
has been suggested that the neuroprotective role of resveratrol, a
polyphenolic compound, is due to its anti-oxidative property
[12,13]. MPP+ is a dopaminergic poison that inhibits complex I of
the mitochondrial electron transfer chain, resulting in oxidative
stress [21]. Therefore, the scavenging of free radicals mediated by
resveratrol helps to reduce a MPP+-induced cytotoxicity. In addi-
tion, AMP-activated protein kinase (AMPK), which is activated in
response to MPP+, prevents cell death [22]. As resveratrol is known
to activate AMPK in neuronal cells, it may exert a pro-survival ef-
fect through AMPK, and not directly through SIRT1 [23]. Therefore,
while it is believed that SIRT1 plays a neuroprotective role in thelsevier B.V. All rights reserved.
220 G. Park et al. / FEBS Letters 585 (2011) 219–224models of AD and HD, its neuroprotective effect in PD is still
unclear.
It needs to be determined whether, and if so, how, SIRT1 di-
rectly regulates MPP+-induced neurotoxicity. To investigate the
precise role of SIRT1 in a model of PD, dopaminergic SH-SY5Y cells
were transfected with SIRT1 siRNA and then treated with MPP+.
Our study demonstrates that the SIRT1-mediated transcriptional
upregulation of pro-apoptotic gene is harmful to MPP+-treated
dopaminergic neuronal cells. Therefore, SIRT1 inhibition would
be a beneﬁcial means of reducing the neuronal cell death in PD.0
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Fig. 1. SIRT1 deﬁciency enhances cell survival in response to MPP+. (A) SH-SY5Y
cells were treated with various concentrations of MPP+ for 24 h (upper). Cleavage of
PARP-1 indicated by arrow was determined in SH-SY5Y cells treated with 1 mM of
MPP+ for the indicated times (lower). (B) Growth of SH-SY5Y cells transfected with
either control siRNA or SIRT1 siRNA was determined following treatment of MPP+
for 24 h. All values are expressed as the means of four independent experiments.
⁄Statistical signiﬁcance, P < 0.05.2. Materials and methods
2.1. Cell culture and transfection
SH-SY5Y human neuroblastoma cells were incubated in Dul-
becco’s modiﬁed essential medium containing 10% fetal bovine
serum supplemented with 1 mM of sodium pyruvate. Lipofect-
amine RNAiMAX reagent (Invitrogen) was used to transfect
20 nM of control, or SIRT1 siRNA (Samchully Pharm. Co. Ltd.)
according to the manufacturer’s instructions. The sequences of
the siRNA duplexes were as follows: control siRNA, CGUACGCG-
GAAUACUUCGAdTdT; SIRT1 siRNA, UGAAGUGCCUCAGAUAUUA
dTdT. BNIP2 cDNA and BNIP2 short hairpin RNAs (shRNAs) were
purchased from Open Biosystems. BNIP2 was cloned into the
pCMV-Tag2B vector. FLAG-tagged BNIP2 and shBNIP2 were trans-
fected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions.
2.2. AlamarBlue assay
Forty-eight hours after transfection of the control or SIRT1 siR-
NAs, 1  104 cells were plated in a 96-well plate, and then treated
with 1 mM of MPP+ (Sigma D048) for 24 h. AlamarBlue dye (Invit-
rogen) was added to each well and the plate was incubated for 4 h
at 37 C to allow cells to convert resazurin to resoruﬁn. The absor-
bance was measured at 570 nm, using 600 nm as a reference
wavelength.
2.3. Hoechst staining
Cells were ﬁxed using 3% of paraformaldehyde for 10 min at
room temperature, and were then permeabilized with 0.5% Triton
X-100. The cells were stained with Hoechst 33342 (Invitrogen,
H21492) for 10 min at room temperature. Apoptotic bodies were
detected using a ﬂuorescent microscope.
2.4. Western blotting
The cell pellet was lysed using NETN buffer (100 mM NaCl,
1 mM EDTA, 20 mM Tris–HCl, pH 8.0, 0.5% Nonidet P-40, 50 mM
b-glycerophosphate, 10 mM NaF) with protease inhibitor (Calbio-
chem, 539134) for 10 min on ice. The crude extracts were boiled
in the Laemmli buffer and then loaded onto an SDS–polyacryl-
amide gel. The antibodies used for Western blotting are as follows:
anti-Caspase-3 (Cell signaling, 9665), anti-FLAG (Sigma, F3165),
anti-GAPDH (Santa Cruz, sc-25778), anti-PARP-1 (Santa Cruz, sc-
7150), and anti-SIRT1 (Epitomics, 1104-1).
2.5. RT-PCR
Total RNA was isolated from MPP+-treated cells with Trizol re-
agent (Invitrogen, BRL-15596-018), and was used to synthesize
cDNA using PrimeScript™ reverse transcriptase (Takara). The se-
quences of each forward (F) and reverse (R) primer used for PCRwere as follows: BNIP2-F, TCTTCCAAAACCCAAGACTA; BNIP2-R,
ATAGCTCCAAAGTGCCAATA; BCL-xL-F, GGAGCTGGTGGTTGACTTT
C; BCL-xL-R, TGGGATGTCAGGTCACTGAA; GAPDH-F, GAGTCAAC
GGATTTGGTCGT; GAPDH-R, GGTGCTAAGCAGTTGGTGGT; SIRT1-F,
CCTGTGAAAGTGATGAGGAGGATAG; SIRT1-R, TTGGATTCCCGCAAC
CTG; 18S rRNA-F, CAGCCACCCGAGATTGAGCA; 18S rRNA-R,
TAGTAGCGACGGGCGGTGTG.
3. Results
3.1. SIRT1 deﬁciency protects SH-SY5Y cells from MPP+-induced
cytotoxicity
The exact role of SIRT1 in MPP+-induced neurocytotoxicity is
still unknown. To examine the effect of SIRT1 on cell survival fol-
G. Park et al. / FEBS Letters 585 (2011) 219–224 221lowing MPP+ treatment, SH-SY5Y dopaminergic cells were trans-
fected with SIRT1 siRNA and were then treated with MPP+ at vari-
ous concentrations for 24 h. Treatment of 1 mM MPP+ for 24 h was
sufﬁcient to result in the 50% death of the SH-SY5Y cells through
apoptosis, as determined by the cleavage of PARP-1, an apoptotic
marker (Fig. 1A). Under these apoptotic conditions, SIRT1-deﬁcient
cells showed greater cell survival than the control cells (Fig. 1B).
The knock-down efﬁciency of SIRT1 siRNA was veriﬁed by Western
blotting (Fig. 1B). It indicates that SIRT1 deﬁciency protects cells
against MPP+-induced cytotoxicity.A
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Fig. 3. SIRT1 deﬁciency inhibits transcriptional upregulation of the pro-apoptotic gene, B
or SIRT1 siRNA. Forty-eight hours after transfection, cells were treated with 1 mM of MP
(B) The mRNA expression level of each gene was quantiﬁed and normalized to GAPDH u
experiments. ⁄Statistical signiﬁcance, P < 0.05.3.2. SIRT1 deﬁciency inhibits MPP+-induced apoptosis in SH-SY5Y cells
The depletion of SIRT1 attenuated cell death in response to the
dopaminergic neurotoxin, MPP+. Therefore, to determine whether
the protective effect of the SIRT1 siRNA occurred through the inhi-
bition of apoptosis, we investigated the cleavage of caspase-3 and
PARP-1, and apoptotic body formation, following treatment with
1 mM MPP+ for 24 h. The cleaved bands of caspase-3 and PARP-1,
at 17/19 kDa and 85 kDa, respectively, disappeared dramatically
in SIRT1-deﬁcient cells (Fig. 2A). In addition, apoptotic bodies were0.0
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222 G. Park et al. / FEBS Letters 585 (2011) 219–224signiﬁcantly abolished in SIRT1-deﬁcient cells compared to control
cells (Fig. 2B). These results demonstrate that SIRT1 depletion pro-
tects MPP+-treated cells from cell death via apoptosis.
3.3. SIRT1 deﬁciency results in the downregulation of pro-apoptotic
genes
To obtain an insight into the mechanism by which SIRT1 deﬁ-
ciency protects SH-SY5Y cells from MPP+-induced apoptosis, we
looked at the ratio of pro-apoptotic to anti-apoptotic genes, which
is a good indicator for evaluating the extent of apoptosis [24]. The
expression ratio of BNIP2, a potential pro-apoptotic gene [25], to
BCL-xLwas determined. Interestingly, the ratio of BNIP2/BCL-xL de-
creased in SIRT1-depleted, MPP+-treated cells (Fig. 3A and B). Over-
all, these results suggest that the absence of SIRT1 fails to upregulate
an apoptotic ratio such as BNIP2/BCL-xL in response to MPP+.
3.4. BNIP2 is a possible mediator of MPP+-induced apoptosis
The present study showed the increase in BNIP2/BCL-xL ratio in
MPP+-treated SH-SY5Y cells. Therefore, we sought to determine
whether expression of the BNIP2 gene regulates MPP+-inducedBA
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Fig. 4. BNIP2 regulates MPP+-induced PARP-1 cleavage. BNIP2 is either overexpressed (
shBNIP2 #1 with SIRT1 siRNA (C) in SH-SY5Y cells. After treatment with 1 mM of MPP+ f
BCL-xL and BNIP2/18S rRNA were quantiﬁed using densitometry.apoptosis. SH-SY5Y cells were transfected with either BNIP2 cDNA
or BNIP2 shRNA and then the cleavage of PARP-1 was determined
following MPP+-treatment. When SH-SY5Y cells were transfected
with ectopic BNIP2, we observed enhanced PARP-1 cleavage
(Fig. 4A). In contrast, the BNIP2-shRNA transfected SH-SY5Y cells
showed less PARP-1 cleavage (Fig. 4B). It suggests that BNIP2
may play a role as one of the important regulators in MPP+-induced
apoptosis. Next, to determine the effect of SIRT1 on BNIP2-depen-
dent MPP+-induced apoptosis, both SIRT1 and BNIP2 were
knocked-down in SH-SY5Y cells. Following MPP+-treatment, the
co-depleted cells showed the similar PARP-1 cleavage and BNIP2/
BCL-xL ratio, which was shown in cells with BNIP2 knock-down
alone (Fig. 4C). It suggests that SIRT1 deﬁciency might attenuate
MPP+-induced apoptosis through BNIP2.4. Discussion
Althoughnumerous reportshave shownapotential neuroprotec-
tive effect of an anti-oxidative compound, resveratrol considered to
be an SIRT1 activator, it is still unknown whether SIRT1 directly
protects dopaminergic cells from MPP+-induced cytotoxicity. ToNA
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or 24 h, PARP-1 cleavage was determined by Western blotting. The ratios of BNIP2/
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siRNA to downregulate the expression of SIRT1. SIRT1 deﬁciency re-
duced apoptosis in MPP+-treated SH-SY5Y cells. Interestingly, we
found that a potential apoptotic indicator, BNIP2/BCL-xL ratio was
regulated by SIRT1, and further BNIP2 itself controlled the apoptotic
responses to theMPP+ toxin.Overall, the present studydemonstrates
that SIRT1 inhibition protects dopaminergic cells from MPP+-induced
apoptosis through the regulation of apoptotic genes.
The present ﬁndings are contrary to previous reports showing
that SIRT1 plays a protective role against neurodegeneration in
conditions such as ALS, AD, and HD. However, a few studies have
suggested that the SIRT1 inhibition does have a neuroprotective ef-
fect. The inhibition of SIRT1 activity by nicotinamide promotes
neuronal survival following acute anoxic injury and ﬂuid percus-
sion injury [26,27]. It has also been reported that SIRT1 inhibition
mediated by treatment with nicotinamide or sirtinol, renders neu-
rons resistant to oxidative stress through the deactivation of IRS-2/
Ras/ERK signaling [28]. Therefore, based on the present ﬁndings
that SIRT1 inhibition exerts a beneﬁcial effect against MPP+ toxin,
the absence of the SIRT1 protein and/or activity would be a critical
factor in neuroprotection in a model of PD.
The mechanism by which SIRT1 participates in MPP+-induced
apoptosis is still in question. SIRT1 is known to regulate apoptosis
in various types of cells in response to different stresses by deacet-
ylating several transcription factors. For example, SIRT1-mediated
deacetylation of p53 and FOXO blocks apoptosis in response to
genotoxic stresses [29]. In contrast, deacetylation of the NF-jB
transcription factor by SIRT1 enhances apoptosis following TNF-a
treatment [30]. This suggests that SIRT1 determines the fate of
apoptosis depending on the type of cellular stress and/or the tran-
scription factor targeted for deacetylation. It remains to be deter-
mined which transcription factor would be targeted in order to
exert the control over MPP+-induced apoptosis.
Apoptosis is regulated by BCL-2 family, which comprises pro-
apoptotic and anti-apoptotic proteins. Among the BCL-2 gene fam-
ily, there is a unique gene product called BNIP2/NIP2, which con-
tains a BCH domain (BNip2 and Cdc42GAP Homology) instead of
a BH3 domain, a conserved motif in the BCL-2 family. BNIP2 was
originally identiﬁed as a protein associated with adenovirus E1B
19 kDa and BCL2, and was thought to promote cell survival [31].
However, several studies have proposed that BNIP2 contributes
to the inhibition of estrogen-mediated cell survival in neuronal
cells and monoblastoid cells [25,32,33]. In addition, it has been
shown that the BCH domain of BNIP2 is required for apoptosis
[34,35]. Therefore, as observed in Figs. 3 and 4, the downregulation
of BNIP2, partially mediated by SIRT1 deﬁciency, protects cells
from MPP+-induced apoptosis, while the upregulation of BNIP2 is
one of the essential factors for MPP+-induced cytotoxicity. The
unresolved question is the mechanism by which BNIP2 is trans-
criptionally downregulated in SIRT1-deﬁcient cells. This phenome-
non is explained by a recent ﬁnding that chromatin
immunoprecipitation on chip in vitro analysis identiﬁed BNIP2 as
one of the candidate genes whose promoter is directly regulated
by SIRT1 recruitment [36]. Although the regulation of BNIP2 by
SIRT1 is still in doubt, it will be of interest to explore the role of
BNIP2 in MPP+-induced apoptosis.
The ﬁndings of the present study suggest a new model whereby
SIRT1 inhibition is required for the survival of dopaminergic cells
following treatment with MPP+ neurotoxin. Therefore, the small
molecule inhibitors of SIRT1 could be developed as therapeutic
drugs for use against Parkinson’s disease.
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